Becton, Dickinson and Company (BDX) is a global medical technology firm dedicated to improving healthcare outcomes through innovative products and services across its Medical, Connected Care, BioPharma Systems, and Interventional and Life Sciences segments. Operating within the Healthcare sector's Medical Instruments & Supplies industry, BDX provides a wide array of medical supplies, devices, and diagnostic solutions. The company's recent earnings performance shows consistent beats against analyst estimates. In Q4 2024, BDX reported an actual EPS of $3.43 against an estimate of $2.99, with revenue at $5.17 billion. For Q1 2025, EPS was $3.35 compared to an estimate of $3.28, and revenue reached $5.27 billion. The trend continued into Q2 2025 with an EPS of $3.68 versus an estimate of $3.40, and revenue of $5.51 billion, followed by Q3 2025 where EPS was $3.96 against an estimate of $3.91, with revenue at $5.89 billion. This demonstrates a pattern of exceeding EPS expectations in the last four reported quarters, with revenue generally showing a positive growth trajectory over this period. Historically, BDX has shown a strong ability to surpass analyst earnings estimates, indicating robust operational performance and effective market strategies. Recent news indicates significant progress in BDX's interventional and home care segments, with clinical trials supporting EU approval for the Liverty TIPS Stent Graft and positive efficacy for the PureWick Urine Collection System. The company has also launched its HemoSphere Stream platform for continuous, noninvasive blood pressure monitoring and AI-enabled solutions in Europe. Goldman Sachs initiated coverage with a Neutral rating and a $167 price target. Investors will be closely watching the upcoming Q2 fiscal 2026 earnings report for financial performance updates and the progression of key product trials, such as the Liverty TIPS Stent Graft. Key will be observing the market adoption and clinical impact of new product launches and the continued success in its interventional and home care segments.
